Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Pan-cancer polygenic risk score associates with cancer susceptibility following kidney transplantation
Jarmo Ritari, Kati Hyvärinen, Kirsi Jahnukainen, FinnGen Consortium, Jukka Partanen, Ilkka Helanterä, Timo Jahnukainen
Jarmo Ritari, Kati Hyvärinen, Kirsi Jahnukainen, FinnGen Consortium, Jukka Partanen, Ilkka Helanterä, Timo Jahnukainen
View: Text | PDF
Clinical Research and Public Health Nephrology Oncology

Pan-cancer polygenic risk score associates with cancer susceptibility following kidney transplantation

  • Text
  • PDF
Abstract

BACKGROUND Cancer accounts for over 20% of late posttransplant mortality, yet the contribution of genetic susceptibility to posttransplant cancer risk remains unclear. This study investigates germline genetic risk factors for posttransplant cancer in the Finnish population using data from the FinnGen cohort.METHODS A pan-cancer polygenic risk score (PRS) was constructed using genetic variants identified in UK and US populations to assess the influence of common germline variants on time to first cancer diagnosis in 1,802 Finnish kidney transplant recipients (KTRs), of whom 317 developed posttransplant cancer. The PRS was first validated in the FinnGen non-transplantation cohort and subsequently applied to KTRs, with replication in lung and liver transplant recipients (n = 476). Functional relevance was explored by assessing associations between the PRS and expression levels of 2,923 plasma proteins in the UK Biobank (n = 53,013).RESULTS Compared with a matched non-transplantation cohort (n = 68,294), KTRs exhibited earlier cancer onset. The PRS was significantly associated with time to first cancer diagnosis in the non-transplantation population (HR 1.04, 95% CI 1.038–1.056, P = 3.75 × 10–25). Among KTRs younger than 40 years, higher PRS was associated with earlier cancer onset (HR 1.08, 95% CI 1.01–1.17, P = 0.036), indicating a stronger genetic effect at younger ages. The PRS significantly (Bonferroni < 0.05) altered the regulation of 87 plasma proteins, several of which were known cancer-related markers.CONCLUSION Inherited genetic predisposition, captured by pan-cancer PRS, may contribute to individual susceptibility to cancer after solid organ transplantation, particularly at younger ages.FUNDING State research funding (Helsinki and Uusimaa Health District), the Foundation for Pediatric Research, and the Sigrid Jusèlius Foundation.

Authors

Jarmo Ritari, Kati Hyvärinen, Kirsi Jahnukainen, FinnGen Consortium, Jukka Partanen, Ilkka Helanterä, Timo Jahnukainen

×

Figure 4

Cancer risk in KT recipients.

Options: View larger image (or click on image) Download as PowerPoint
Cancer risk in KT recipients.
(A) Kaplan-Meier survival curves for the t...
(A) Kaplan-Meier survival curves for the time to the first cancer diagnosis in KT cohort versus non-transplantation cohort in FinnGen, limited to individuals sampled below 40 years of age. The P value was obtained from the coxph model (see Methods) adjusted for age, sex, population stratification, genetic cancer risk, BMI, and smoking. (B) Kaplan-Meier curves for the time to the first cancer diagnosis by binned patient age at KT. The P value was obtained from a coxph model as described above. (C) Kaplan-Meier curves for the time to the first cancer diagnosis in KT recipients under 40 years of age at the time of KT, stratified for high (+1 SD) and low (–1 SD) pan-cancer PRS. The P value was obtained from a coxph model for continuous PRS as described above, including transplantation age as a covariate, but excluding BMI and smoking. (D) Pan-cancer PRS coxph model hazard ratio for the first cancer diagnosis as a function of cumulative maximum age at KT, ranging from 18 to 80 years of age at KT. The models are adjusted as described above, including age at KT, but excluding BMI and smoking. (E) Pan-cancer PRS hazard ratios by KT age bins of 10 years, showing higher risk in young patients. The first bin was defined by the youngest age at KT for which the cox model could be fitted without errors. Survival analyses in A–C were performed with multivariable coxph regression. Analysis of trend in D was performed with univariate linear regression.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts